Do Allergy Shots Work for Dust Mites? The Strongest Evidence in SCIT

Most patients with dust mite allergy begin noticing symptom improvement within 3 to 6 months of starting SCIT as their dose builds toward the maintenance threshold. Meaningful rhinitis and asthma symptom reduction is typically well-established by 12 months of treatment. Unlike seasonal pollen SCIT, where you can compare symptom-free periods before and after treatment season-by-season, dust mite SCIT provides year-round relief that accumulates gradually. Research by Lee et al. in 2018 found that treatment duration of 3 or more years was the strongest predictor of clinical remission, with an odds ratio of 7.37. Starting SCIT and continuing through the full 3-year course is therefore critical to achieving durable benefit — not just short-term symptom control.

Yes, and dust mite SCIT has the strongest single-allergen evidence for asthma outcomes of any allergen in immunotherapy. The Abramson Cochrane review (2010) synthesized 88 randomized controlled trials and found SCIT significantly reduced asthma symptom scores (SMD -0.59), medication use (SMD -0.53), and allergen-specific bronchial hyperreactivity. The Number Needed to Treat to prevent one asthma symptom deterioration was 3. SCIT is particularly appropriate for allergic asthma — where IgE-mediated dust mite sensitivity is the confirmed driver — and should only be initiated when asthma is well controlled (FEV1 above 70% predicted). Patients with uncontrolled asthma are at higher risk for systemic reactions and should stabilize their asthma with appropriate controller medications before starting immunotherapy.

Der p 1 is the major allergen from Dermatophagoides pteronyssinus (European house dust mite), and Der f 1 is the major allergen from Dermatophagoides farinae (American house dust mite). Both are cysteine proteases found in dust mite fecal particles and body parts. Most dust-mite-sensitized patients react to both species, which are present simultaneously in household dust across North America. Standardized dust mite extracts used in SCIT target both Der p 1 and Der f 1, typically at a combined 10,000 AU per milliliter. Testing for specific IgE to both allergens separately provides the most accurate picture of your sensitization profile and guides appropriate extract formulation by your allergist.

Environmental controls and SCIT serve complementary roles and work best in combination — neither fully replaces the other for most patients. Mattress and pillow encasements can reduce Der p 1 in mattress dust by up to 90% over six months. Maintaining indoor humidity below 50% inhibits dust mite reproduction significantly. HEPA air filtration reduces airborne mite allergen particles. However, no environmental control strategy modifies your immune response — once the controls are lifted, your allergy returns to baseline. SCIT produces immunological tolerance that persists for years after stopping treatment. The Cochrane review of dust mite avoidance measures (Gotzsche and Johansen, 2008) found limited evidence that avoidance alone produces clinical improvement in asthma. The most effective approach for long-term dust mite allergy management combines SCIT with consistent environmental controls to maximize outcomes.

Yes — Odactra is an FDA-approved sublingual tablet for house dust mite allergic rhinitis, approved in 2017, taken daily at home after the first dose is administered in the doctor's office. Nolte et al. 2016 (n=1,482) demonstrated a 17% total combined rhinitis score reduction versus placebo. Virchow et al. in JAMA 2016 (n=834) showed HDM SLIT tablet reduced the risk of moderate to severe asthma exacerbations — the first allergy immunotherapy trial powered for asthma exacerbations as a primary endpoint. Odactra treats only dust mite allergy; patients sensitized to multiple allergens including pollen or pet dander would need additional therapy. Off-label sublingual drops covering multiple allergens including dust mite are also available through allergists and telehealth services, though they lack the standardized clinical trial data of FDA-approved tablets.

Evidence suggests that dust mite SCIT may reduce the development of new allergen sensitizations, particularly in children. Des Roches et al. in 1997 (n=44 mite-monosensitized children) found that 45% of SCIT-treated children developed no new sensitizations versus 0% of untreated controls over the follow-up period. Eng et al. confirmed sustained protection at 6 and 12 years post-treatment. However, a systematic review by Di Bona in 2017 found that when restricted to randomized trials, the evidence for sensitization prevention is inconclusive — most positive findings come from non-randomized studies that are vulnerable to selection bias. This disease-modification potential is strongest in younger patients with shorter disease duration, making early treatment initiation advantageous for children with emerging dust mite allergy.

During the maintenance phase of dust mite SCIT, injections are typically given every 2 to 4 weeks. This differs from pollen SCIT in one important respect: because dust mite allergen is present year-round with no off-season, dust mite SCIT follows a perennial schedule — there is no summer or winter break. The build-up phase requires one or two injections per week for 3 to 6 months until the maintenance dose is reached. A 2012 AAAAI member survey found that 73% of US practices schedule maintenance injections every 4 weeks. Consistency matters — gaps greater than 3 months typically require dose reduction and may lengthen the timeline. Traditionally this meant roughly 57 to 60 clinic visits over a 3-year course; with at-home SCIT through Curex those injections are self-administered at home instead, with the first dose and every dose change supervised live over Zoom.